-
121por Løndalen, Ayca, Blakkisrud, Johan, Revheim, Mona-Elisabeth, Madsbu, Ulf Erik, Dahle, Jostein, Kolstad, Arne, Stokke, Caroline“…Lesion response was evaluated at 3 and 6 months (PET(3months) and PET(6months)) based on Deauville criteria. Anatomical changes based on ceCT at baseline and at 6 and 12 months were investigated by the sum of perpendiculars (SPD). …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
122por Yu, Shan-Chi, Ko, Kuan-Yin, Teng, Shu-Chun, Huang, Tai-Chung, Lo, Hsiao-Ting, Cheng, Chieh-Lung, Yao, Ming, Hong, Ruey-Long, Chen, Chun-Nan, Chen, Tseng-Cheng, Yang, Tsung-Lin“…Of 10 lymphoma patients, 8 (80%) had a Deauville score of 4–5; they accounted for 30% (8/27) of lymphoma patients with false-positive PET/CT scan results. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
123por AlShehry, Nawal Faiez, Shanker, Raja, Zaidi, Syed Ziauddin Ahmed, AlGhmlas, Fahad, Motabi, Ibraheem Hussein, Iqbal, Shahid, Butt, Ahmad Ali, AlShehri, Hassan, Tailor, Imran Khan, Altaf, Syed Yasir, AlGhamdi, Mubarak, Marie, Mohammed, AlFayez, Mansour, Al Zahrani, Kamal, Dwaimah, Mohammed, Al-Halouli, Tahani, Al-Shakweer, Wafaa, AlShehery, Maied Zaher, Zaidi, Abdul Rehman Zia, Gill, Atta Munawar, Albtoosh, Belal Mohammed, Ahmed, Musab“…Metabolic response on follow-up PET/CT was assessed using the maximum standardized uptake value (SUVmax) and Deauville criteria (DC). We aimed to obtain the best SUVmax and DC to predict optimal survival rates, risk stratification, and optimize therapeutic strategies. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
124por Yuan, Tingting, Zhang, Yuewei, Chen, Xuetao, Wei, Maomao, Zhu, Hua, Song, Yuqin, Yang, Zhi, Zhu, Jun, Wang, Xuejuan“…PET during the interim was evaluated using Deauville 5-point scales (5-PS), ΔSUV(max) criteria, and the Peking criteria which interpreted based on the maximum standard uptake of the liver (SUV(max-liver)). …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
125por Al-Ibraheem, Akram, Anwer, Farah, Juweid, Malik E., Shagera, Qaid Ahmed, Khalaf, Aysar N., Obeidat, Shahed, Mansour, Areen, Ma’koseh, Mohammad, Halahleh, Khalid, Jaradat, Imad, Almasri, Nidal, Mansour, Asem“…The response status on iPET was defined according to the standard five-point Deauville scores (DS) as follows: complete metabolic response (CMR, DS 1–3) and non-complete metabolic response (nCMR) (DS 4 and 5). …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
126por Galtier, Jean, Vercellino, Laetitia, Chartier, Loic, Olivier, Pierre, Tabouret-Viaud, Claire, Mesguich, Charles, Di Blasi, Roberta, Durand, Amandine, Raffy, Léo, Gros, François-Xavier, Madelaine, Isabelle, Meignin, Veronique, Mebarki, Miryam, Rubio, Marie-Thérèse, Feugier, Pierre, Casasnovas, Olivier, Meignan, Michel, Thieblemont, Catherine“…In total, 119 (75%) patients reached M1 evaluation; 64 (53%, 64/119) had a complete response (CR); 91% were Deauville Score (DS) 1-3. Progression-free survival (PFS) and overall survival (OS) were significantly worse in patients with DS-5 at M1, than in patients with DS 1-3 (PFS hazard ratio [HR]=6.37, 95% confidence interval [CI]: 3.5-11.5 vs. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
127por Fatima, Nosheen, Zaman, Maseeh Uz, Zaman, Areeba, Zaman, Unaiza, Tahseen, Rabia, Zaman, Sidra“…%Δ changes in fasting blood sugar, (18)FDG dose, uptake time, and liver SUV mean were 3.96%, 2.83%, 2.49%, and 12.15%, respectively. Based on Deauville's scoring, cohort was divided into responders having Score 1–3 (49/97) and nonresponders having Score 4–5 (48/97). …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
128por Paone, Gaetano, Raditchkova-Sarnelli, Mariana, Ruberto-Macchi, Teresa, Cuzzocrea, Marco, Zucca, Emanuele, Ceriani, Luca, Giovanella, Luca“…Two blinded observers independently assessed PET/ldCT and PET/ceCT applying the Deauville score (DS) and Lugano classification criteria. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
129por Sachpekidis, Christos, Merz, Maximilian, Raab, Marc-Steffen, Bertsch, Uta, Weru, Vivienn, Kopp-Schneider, Annette, Jauch, Anna, Goldschmidt, Hartmut, Dimitrakopoulou-Strauss, Antonia“…PET/CT analysis was based on the IMPeTUs criteria, which take into consideration—among others—the metabolic state of the bone marrow based on the 5-point Deauville score (DS), the number and metabolic state of focal [(18)F]FDG-avid lesions, as well as the presence of paramedullary disease (PMD) and extramedullary disease (EMD). …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
130por Kiamanesh, Zahra, Ayati, Narjess, Sadeghi, Ramin, Hawkes, Eliza, Lee, Sze Ting, Scott, Andrew M.“…In anti-CD20 therapy, the highest pooled hazard ratios (HRs) of baseline, early, and late response monitoring parameters for progression-free survival (PFS) belong to metabolic tumor volume (MTV) (3.19 (95%CI: 2.36–4.30)), maximum standardized uptake value (SUVmax) (3.25 (95%CI: 2.08–5.08)), and Deauville score (DS) (3.73 (95%CI: 2.50–5.56)), respectively. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
131por Bonomo, P., Merlotti, A., Morbelli, S., Berti, V., Saieva, C., Bergesio, F., Bacigalupo, A., Belgioia, L., Franzese, C., Lopci, E., Casolo, A., D’Angelo, E., Alterio, D., Travaini, L., Berretta, L., Pirro, V., Ursino, S., Volterrani, D., Roncali, M., Vigo, F., Cicchetti, S., Scalone, F., Belli, G., Cauda, S., Desideri, I., Russi, E., Livi, L., Bianchi, A.“…Response to treatment was evaluated according to Hopkins, Cuneo, and Deauville criteria. The primary endpoint of the study was to evaluate the PPV of Cuneo score in assessing locoregional control (LRC). …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
132por Eertink, J. J., Arens, A. I. J., Huijbregts, J. E., Celik, F., de Keizer, B., Stroobants, S., de Jong, D., Wiegers, S. E., Zwezerijnen, G. J. C., Burggraaff, C. N., Boellaard, R., de Vet, H. C. W., Hoekstra, O. S., Lugtenburg, P. J., Chamuleau, M. E. D., Zijlstra, J. M.“…METHODS: Interim PET/CT (I-PET) and end of treatment PET/CT (EoT-PET) scans of 81 MYC + and 129 MYC- DLBCL patients from 2 HOVON trials were reviewed using the Deauville 5-point scale (DS). DS1-3 was regarded as negative and DS4-5 as positive. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
133por Jin, Jia, Ji, Dongmei, Xia, Zuguang, Xue, Kai, Zhang, Qunling, Liu, Yizhen, Cao, Junning, Hong, Xiaonan, Gu, Juan J., Guo, Ye, Lv, Fangfang“…Patients with negative PET/CT (Deauville scores 1–2) received 2 additional cycles of rituximab monotherapy, unless they had any risk factors (primary mediastinal large B-cell lymphoma, extranodal primary or bulky disease). …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
134por Zhang, Peiling, Yang, Xiuxiu, Cao, Yang, Wang, Jue, Zhou, Mi, Chen, Liting, Wei, Jia, Mao, Zekai, Wang, Di, Xiao, Yi, Zhu, Haichuan, Zhang, Shangkun, Zhang, Tongcun, Zhang, Yicheng, Zhou, Jianfeng, Huang, Liang“…Three patients (50.0%) relapsed for ≥ 2 times and 3 patients (50.0%) had primary refractory diseases. All had a Deauville score of 4 or 5, and 5 patients (83.3%) had a stable or progressive disease (SD/PD) at enrollment. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
135por Dang, Jun, Peng, Xiaojuan, Wu, Ping, Yao, Yutang, Tan, Xiaofei, Ye, Zhenyan, Jiang, Xuemei, Jiang, Xiao, Liu, Yongli, Chen, Shirong, Cheng, Zhuzhong“…The chi-squared test showed that TMTV0, STMTV0, Dmax, SUVmax1, TMTV1, TTLG1, %ΔSUVmax, Deauville score, IPI, Ann Arbor stage, and LDH were associated with patient prognosis (P < 0.05). …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
136por Kucukyurt, Selin, Şahin, Kübra, Yılmaz, Umut, Erçalışkan, Abdülkadir, Özkan Tekin, Tuba, Ortaboz, Damla, Elverdi, Tuğrul, Salihoğlu, Ayşe, Ar, Muhlis Cem, Öngören, Şeniz, Başlar, Zafer, Eskazan, Ahmet Emre“…PET scans were performed at baseline, after two cycles of chemotherapy, and end of treatment (EOT). The Deauville five-point scale (5-PS) was used in the initial staging and assessment of treatment response. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
137por Koh, Dow-Mu, Kaste, Sue Creviston, Vinnicombe, Sarah J., Morana, Giovanni, Rossi, Andrea, Herold, Christian J., McLoud, Theresa C., Frey, Kirk A., Gebauer, Bernhard, Roebuck, Derek, Fütterer, Jurgen J., Towbin, Alexander J., Huisman, Thierry A. G., Smets, Anne M. J. B., Morana, Giovanni, Lee, Jeong Min, Chandarana, Hersh, Mayerhoefer, Marius E., Raderer, Markus, Haug, Alexander, Eiber, Matthias, Gebauer, Bernhard, Rockall, Andrea, Sohaib, Aslam, Warbey, Victoria S, Vargas, Hebert Alberto, Koh, Dow-Mu, Heiken, Jay P., Francis, Isaac R., Al-Hawary, Mahmoud M., Kaza, Ravi K., Morana, Giovanni, D’Onofrio, Mirko, Thoeny, Harriet C., King, Ann D., Morana, Giovanni, Piccardo, Arnoldo, Garrè, Maria Luisa, Rossi, Andrea, Vargas, Hebert Alberto, McLoud, Theresa C., Reed, Nick, Rodriguez-Galindo, Carlos, Chandarana, Hersh, Vargas, Hebert Alberto, Francis, Isaac R., Wasnik, Ashish P., Diederich, Stefan, Fütterer, Jurgen J., Oyen, Wim J. G., Chaw, Cheng Lee, van As, Nicholas, Vieira, Igor, De Keyzer, Frederik, Dresen, Elleke, Han, Sileny, Vergote, Ignace, Moerman, Philippe, Amant, Frederic, Koole, Michel, Vandecaveye, Vincent, Dresen, R., De Vuysere, S., De Keyzer, F., Van Cutsem, E., D’Hoore, A., Wolthuis, A., Vandecaveye, V., Pricolo, P., Alessi, S., Summers, P., Tagliabue, E., Petralia, G., Pfannenberg, C., Gückel, B., Schüle, S. C., Müller, A. C., Kaufmann, S., Schwenzer, N., Reimold, M., la Fougere, C., Nikolaou, K., Martus, P., Cook, G. J., Azad, G. K., Taylor, B. P., Siddique, M., John, J., Mansi, J., Harries, M., Goh, V., Seth, S., Burgul, R., Seth, A., Waugh, S., Gowdh, N. Muhammad, Purdie, C., Evans, A., Crowe, E., Thompson, A., Vinnicombe, S., Arfeen, F., Campion, T., Goldstraw, E., D’Onofrio, M., Ciaravino, V., Crosara, S., De Robertis, R., Mucelli, R. Pozzi, Uhrig, M., Simons, D., Schlemmer, H., Downey, Kate, Murdoch, S., Al-adhami, A. S., Viswanathan, S., Smith, S., Jennings, P., Bowers, D., Soomal, R., Smith, S., Jennings, P., Bowers, D., Soomal, R., Mutala, T. M., Odhiambo, A. O., Harish, N., Pricolo, P., Alessi, S., Summers, P., Tagliabue, E., Petralia, G., Hall, M., Sproule, M., Sheridan, S., Thein, K. Y., Tan, C. H., Thian, Y. L., Ho, C. M., De Luca, S., Carrera, C., Blanchet, V., Alarcón, L., Eyheremnedy, E., Choudhury, B. K., Bujarbarua, K., Barman, G., Cook, G. J., Lovat, E., Siddique, M., Goh, V., Ferner, R., Warbey, V. S., Potti, L., Kaye, B., Beattie, A., Dutton, K., Seth, A. A., Constantinidis, F., Dobson, H., Seth, A. A., Constantinidis, F., Dobson, H., Bradley, R., Bozas, G., Avery, G., Stephens, A., Maraveyas, A., Bhuva, S., Johnson, C. A., Subesinghe, M., Taylor, N., Quint, L. E., Reddy, R. M., Kalemkerian, G. P., Zapico, G. González, Jauregui, E. Gainza, Francisco, R. Álvarez, Alonso, S. Ibáñez, Bahillo, I. Tavera, Álvarez, L. Múgica, Francies, O., Wheeler, R., Childs, L., Adams, A., Sahdev, A., De Luca, S. E., Vañek, M. E. Casalini, Pascuzzi, M. D., Gillanders, T., Ramos, P. M., Eyheremendy, E. P., Stove, C., Digby, M., Nazar, M., Wirtz, M., Pascuzzi, M. D., Troncoso, F., Saguier, F., Eyheremendy, E. P., Quint, D. J., Dang, L., Carlson, M., Leber, S., Silverstein, F., Rueben, R., Viswanathan, S., Nazir, B., Teo, T. H., Khoo, J. B., Sharma, K., Gupta, N., Mathew, B., Jeyakumar, T., Harkins, K., Sharma, K., Mathew, B., Gupta, N., Jeyakumar, T., Joshua, S., Christodoulou, D., Gourtsoyianni, S., Jacques, A., Griffin, N., Goh, V., Johnson, C. A., Lee, J., Goodfellow, J. A., Al-adhami, A. S., Viswanathan, S., Bradley, R., Bradley, R., Yong, A., Jenkins, S., Joseph, G., Bhuva, S., Partington, K., Johnson, C. A., Bhuva, S., Subesinghe, M., Taylor, N., Carrera, C., Zanfardini, A., De Luca, S., Alarcón, L., Blanchet, V., Eyheremendy, E. P., Cavanagh, K., Lau, E.“…Mayerhoefer, Markus Raderer, Alexander Haug O18 Managing high-risk and advanced prostate cancer Matthias Eiber O19 Immunotherapy: imaging challenges Bernhard Gebauer O20 RECIST and RECIST 1.1 Andrea Rockall O21 Challenges of RECIST in oncology imaging basics for the trainee and novice Aslam Sohaib O22 Lymphoma: PET for interim and end of treatment response assessment: a users’ guide to the Deauville Score Victoria S Warbey O23 Available resources Hebert Alberto Vargas O24 ICIS e-portal and the online learning community Dow-Mu Koh O25 Benign lesions that mimic pancreatic cancer Jay P Heiken O26 Staging and reporting pancreatic malignancies Isaac R Francis, Mahmoud, M Al-Hawary, Ravi K Kaza O27 Intraductal papillary mucinous neoplasm Giovanni Morana O28 Cystic pancreatic tumours Mirko D’Onofrio O29 Diffusion-weighted imaging of head and neck tumours Harriet C. …”
Publicado 2016
Enlace del recurso
Enlace del recurso
Online Artículo Texto